GlassScriptPhysician profile
Ammar Alrefai
NPI 1720044076
$15,796.85
in general payments reported to CMS, 2019-2025
39 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $1,626 · 2021: $2,458 · 2022: $2,399 · 2023: $3,084 · 2024: $2,906 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,050 · Consulting Fee: $200 · Education: $3.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,049.57 |
| Consulting Fee | $200.00 |
| Education | $3.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,867.22 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $1,547.98 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,163.46 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,017.49 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $1,002.48 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $875.65 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $813.90 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $789.36 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $724.88 | 2020-2025 | Ingrezza |
| Bausch Health US, LLC | $715.93 | 2019-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $658.22 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $571.18 | 2019-2025 | Fanapt, Hetlioz |
| Indivior INC. | $502.59 | 2019-2025 | Sublocade |
| Almatica Pharma LLC | $469.83 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $459.00 | 2022-2025 | Auvelity, Sunosi |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $390.27 | 2019-2024 | Rexulti |
| Neos Therapeutics, LP | $242.17 | 2019-2024 | Adzenys Xr-Odt |
| Allergan, INC. | $223.69 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $200.00 | 2024 | Spravato |
| Avanir Pharmaceuticals, INC. | $196.15 | 2019-2022 | |
| Eisai INC. | $173.25 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $162.25 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $143.90 | 2021-2025 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $140.32 | 2019-2021 | |
| Tris Pharma INC | $125.31 | 2022-2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $107.27 | 2022-2024 | Quviviq |
| Harmony Biosciences LLC | $100.79 | 2023-2025 | Wakix |
| Orexo US, INC. | $64.65 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $53.53 | 2019-2021 | |
| Neuronetics, INC. | $50.60 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $48.33 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $37.25 | 2019-2021 | |
| Shire North American Group INC | $36.10 | 2019 | |
| Braeburn INC. | $23.81 | 2025 | Brixadi |
| Avion Pharmaceuticals | $21.68 | 2023 | Methylphenidate Hydrochloride |
| Vertical Pharmaceuticals, LLC | $21.16 | 2024 | Relexxii |
| Biohaven Pharmaceutical Holding Company LTD. | $20.06 | 2022 | |
| Sage Therapeutics, LLC | $18.71 | 2024 | |
| Collegium Pharmaceutical, INC. | $16.43 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Alrefai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.